Eli Lilly and Company (NYSE:LLY) Stock Price Up 2% on Analyst Upgrade

Eli Lilly and Company (NYSE:LLY)’s share price traded up 2% on Wednesday after Guggenheim raised their price target on the stock from $1,163.00 to $1,183.00. Guggenheim currently has a buy rating on the stock. Eli Lilly and Company traded as high as $922.54 and last traded at $921.0130. 2,619,389 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 3,107,312 shares. The stock had previously closed at $903.02.

LLY has been the topic of a number of other research reports. Daiwa Securities Group increased their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Royal Bank Of Canada assumed coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 target price on the stock. The Goldman Sachs Group set a $1,260.00 target price on Eli Lilly and Company in a research note on Thursday, February 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Finally, Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research note on Friday, March 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,225.33.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Kelonia Therapeutics in a deal worth up to $7B to add an in‑vivo CAR‑T platform and early-stage oncology assets — viewed by analysts as a meaningful step to diversify beyond GLP‑1s and build long‑term growth. Eli Lilly’s US$7b Kelonia Deal Reshapes Oncology And Valuation Story
• Positive Sentiment: Analysts are upping conviction: Guggenheim raised its price target and maintained a Buy, BMO reiterated Outperform with a $1,300 target, and UBS/Bernstein commentary has been bullish — supporting investor demand after the deal and ahead of earnings. Guggenheim Adjusts Price Target on Eli Lilly
• Positive Sentiment: Topline ACHIEVE‑4 results for Foundayo versus insulin glargine and commentary that post‑marketing requirements look manageable have reduced regulatory uncertainty around Lilly’s diabetes franchise. That helps near‑term sentiment on earnings and guidance. Why You Should Not Worry About Eli Lilly and Company’s Foundayo Treatment Prospects
• Neutral Sentiment: Debate over valuation persists — some pieces argue LLY’s premium multiple is justified by growth, others note a wide gap vs. peers like Novo Nordisk; that fuels mixed investor positioning rather than a clear buy/sell signal. Is Eli Lilly Stock Actually … Cheap?
• Negative Sentiment: Competitive and distribution risk: coverage on Amazon potentially entering GLP‑1 distribution has raised concerns about pricing/market share dynamics for the lucrative weight‑loss franchise. Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game.
• Negative Sentiment: Legal and partnership noise: a court allowed Lilly’s lawsuit against a telehealth weight‑loss drug seller to proceed, and Lilly ended a collaboration that returned rights to Rigel — items that create near‑term headline risk and modest uncertainty. Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in LLY. Brighton Jones LLC boosted its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Schnieders Capital Management LLC. boosted its position in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares during the period. Flow Traders U.S. LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at about $749,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 2.0%

The firm’s 50-day simple moving average is $964.35 and its 200-day simple moving average is $984.09. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $870.19 billion, a PE ratio of 40.13, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts expect that Eli Lilly and Company will post 33.95 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.